Paige Fletcher

Paige Fletcher

Auto-generated profile, based on publicly available information

Paige Fletcher

Department of Biomedical and Pharmaceutical Sciences, Center for Environmental Health Sciences, University of Montana, Missoula, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in The Lancet Microbe
Verified
Journal Article
Open access
PFPaige Fletcher
Paige Fletcher
KOKyle O'Donnell
Kyle O'Donnell
FFFriederike Feldmann
Friederike Feldmann
JRJoseph F Rhoderick
Joseph F Rhoderick
CCChad S Clancy
Chad S Clancy
Andrea MarziAndrea Marzi
Andrea Marzi
The Sudan virus (SUDV) outbreaks in recent years, including the most recent outbreak in Uganda, created a public health emergency in the eastern Africa region. There are no licensed vaccines or therapeutics approved against SUDV; however, we have previously developed a vesicular stomatitis virus (VSV)-based vaccine expressing the SUDV glycoprotein and showed its single-dose efficacy in non-human primates (NHPs) with pre-existing Ebola virus (EBOV) immunity. Here, we determined the fast-acting capacity of this vaccine in naive NHPs. In addition, we examined if the licensed VSV-EBOV vaccine would provide any prophylactic benefit against SUDV infection. We used four groups of male cynomolgus macaques (n=6 per group) aged 2·5-4·5 years and weighing 2·9-5·2 kg. NHPs were vaccinated by intramuscular injection 28 days before challenge with either 1 × 107 plaque-forming units (PFUs) VSV-SUDV, VSV-EBOV, or control vaccine (VSV-LASV). Another group was vaccinated with 1 × 107 PFU VSV-SUDV 7 days before challenge. On day 0, all 24 NHPs were challenged with a lethal dose of SUDV (1 × 104 50% tissue culture infectious doses [TCID50] SUDV-Gulu, backtitred as 1·1 × 104 TCID50). We assessed anaesthetised NHPs on days -28, -21, -14, and -7 before challenge; days 0, 3, 6, 9, 14, 21, 28, and 35 after challenge; and at euthanasia (day 42 for survivors). All VSV-SUDV-vaccinated NHPs were protected from disease after the lethal SUDV challenge. In contrast, the VSV-EBOV-vaccinated and control NHPs succumbed to disease between days 5 and 7 after challenge presenting with classical signs of Sudan virus disease associated with high-titre viraemia (>1 × 108 TCID50 per mL), high viral organ load (>1 × 108 TCID50 per g), dysregulated cytokine profiles, and typical pathological changes. The humoral immune response in the NHPs vaccinated with VSV-SUDV 1 month before challenge resulted in a profound and sustained serum antibody response (20 000-30 000 U/mL) with a diverse functionality profile (antibody-dependent cellular phagocytosis and antibody-dependent complement), which was not observed to the same extent in NHPs vaccinated 1 week before challenge. We showed that a single dose of VSV-SUDV protected NHPs from lethal SUDV infection within 1 week. The fast-acting nature highlights VSV-SUDV as an ideal countermeasure for ring vaccination during outbreaks of Sudan virus disease pending further preclinical and clinical assessment. In contrast, VSV-EBOV provided no relevant protection against SUDV infection in NHPs, highlighting the need for species-specific filovirus vaccines. National Institutes of Health, US Department of Health and Human Services.

31 July 2023 in Emerging Microbes & Infections
Verified
Journal Article
Open access
PFPaige Fletcher
Paige Fletcher
KOKyle L. O’DOnnell
Kyle L. O’DOnnell
BDBrianna M. Doratt
Brianna M. Doratt
DMDelphine C. Malherbe
Delphine C. Malherbe
CCChad S. Clancy
Chad S. Clancy
Andrea MarziAndrea Marzi
Andrea Marzi
Taï Forest virus (TAFV) is a lesser-known ebolavirus that causes lethal infections in chimpanzees and is responsible for a single human case. Limited research has been done on this human pathogen; however, with the recent emergence of filoviruses in West Africa, further investigation and countermeasure development against this virus is warranted. We developed a vesicular stomatitis virus (VSV)-based vaccine expressing the TAFV glycoprotein as the viral antigen and assessed it for protective efficacy in nonhuman primates (NHPs). Following a single high-dose vaccination, NHPs developed antigen-specific binding and neutralizing antibodies as well as modest T cell responses. Importantly, all vaccinated NHPs were uniformly protected from disease after lethal TAFV challenge while the naïve control group succumbed to the disease. Histopathologic lesions consistent with filovirus disease were present in control NHPs but were not observed in vaccinated NHPs. Transcriptional analysis of whole blood samples obtained after vaccination and challenge was performed to gain insight into molecular underpinnings conferring protection. Differentially expressed genes (DEG) detected 7 days post-vaccination were enriched to processes associated with innate immunity and antiviral responses. Only a small number of DEG was detected in vaccinated NHPs post-challenge while over 1,000 DEG were detected in control NHPs at end-stage disease which mapped to gene ontology terms indicative of defense responses and inflammation. Taken together, this data demonstrates the effective single-dose protection of the VSV-TAFV vaccine, and its potential for use in outbreaks.

4 November 2020 in Journal of Toxicology and Environmental Health, Part A
Verified
Journal Article
Closed access
PFPaige Fletcher
Paige Fletcher
RHRaymond F. Hamilton
Raymond F. Hamilton
JRJoseph F. Rhoderick
Joseph F. Rhoderick
JPJames J. Pestka
James J. Pestka
AHAndrij Holian
Andrij Holian
Inhalation of particles results in pulmonary inflammation; however, treatments are currently lacking. Docosahexaenoic acid (DHA) is an omega-3 polyunsaturated fatty acid shown to exhibit anti-inflammatory capabilities. The impact of DHA on particle-induced inflammation is unclear; therefore, the aim of this study was to examine the hypothesis that DHA downregulates macrophage inflammatory responses by altering phagolysosomal membrane permeability (LMP) and shifting macrophage phenotype. Isolated Balb/c alveolar macrophages (AM) were polarized into M1, M2a, M2b, or M2c phenotypes in vitro, treated with DHA, and exposed to a multi-walled carbon nanotube (MWNCT) or crystalline silica (SiO2). Results showed minimal cytotoxicity, robust effects for silica particle uptake, and LMP differences between phenotypes. Docosahexaenoic acid prevented these effects to the greatest extent in M2c phenotype. To determine if DHA affected inflammation similarly in vivo, Balb/c mice were placed on a control or 1% DHA diet for 3 weeks, instilled with the same particles, and assessed 24 hr following instillation. Data demonstrated that in contrast to in vitro findings, DHA increased pulmonary inflammation and LMP. These results suggest that pulmonary responses in vivo may not necessarily be predicted from single-cell responses in vitro.

10 February 2021 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
PFPaige Fletcher
Paige Fletcher
RHRaymond F. Hamilton
Raymond F. Hamilton
JRJoseph F. Rhoderick
Joseph F. Rhoderick
BPBritten Postma
Britten Postma
MBMary Buford
Mary Buford
AHAndrij Holian
Andrij Holian

15 October 2021 in Inflammation
Verified
Journal Article
Closed access
PDF file
PFPaige Fletcher
Paige Fletcher
RHRaymond F. Hamilton
Raymond F. Hamilton
JRJoseph F. Rhoderick
Joseph F. Rhoderick
BPBritten Postma
Britten Postma
MBMary Buford
Mary Buford
AHAndrij Holian
Andrij Holian

19 November 2026 in Research Square
Verified
Preprint
Open access
KRKyle Rosenke
Kyle Rosenke
KOKyle O'DOnnell
Kyle O'DOnnell
PFPaige Fletcher
Paige Fletcher
TTTipih Thomas
Tipih Thomas
AGAmanda Griffin
Amanda Griffin
HFHeinz Feldmann
Heinz Feldmann
The 2026 Bundibugyo virus (BDBV) disease outbreak in the Democratic Republic of the Congo (DRC) was declared a public health emergency (PHEIC) in May 2026 (1). Regional security concerns, debilitated medical infrastructure, diagnostic limitations, and lack of approved BDBV–specific medical countermeasures have contributed to rapid escalation of the outbreak (2). Currently, there are no licensed medical countermeasures for BDBV (3). Several BDBV-specific vaccines are in development (4), including a vesicular stomatitis virus (VSV)–based vaccine expressing the BDBV glycoprotein which has demonstrated strong preclinical efficacy (5-7); however, these candidates have not yet completed clinical evaluation. A licensed VSV-based vaccine expressing the Ebola virus glycoprotein (VSV-EBOV) (8) is available for human use and clinical (ERVEBO) and research grade (VSV-EBOV) material has been shown to elicit cross-reactive, cross-neutralizing and inconclusive cross-protective immune responses against the related BDBV (5,9-14). ERVEBO’s protective efficacy against BDBV, however, has not been formally established in the standard macaque model of BDBV infection. Macaques received a single human dose of ERVEBO or an unrelated VSV-based control vaccine and were challenged with BDBV 14 days after vaccination. ERVEBO vaccinated macaques exhibited significantly reduced clinical disease and strikingly increased survival, as well as significantly reduced viremia, mucosal viral shedding and disease-associated biochemistry markers consistent with protection against BDBV-mediated hepatorenal disease. These findings indicate that ERVEBO can rapidly mediate cross-protective immunity against BDBV.